Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

818651

registered interest
date	08/01/2018
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Government response to the Accelerated Access Review published in November 2017, what plans his Department has to streamline existing routes to market for medical technologies, devices and diagnostics.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	121415
answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>We are introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. A new Accelerated Access Collaborative (AAC) chaired by Sir Andrew Witty, will develop and own the Accelerated Access Pathway which will be operational from April 2018. All products including medical technologies, devices and diagnostics will be eligible for selection. In addition to the new Pathway, the AAC will also make recommendations to the Government and its partners about opportunities to further streamline existing routes to market.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 12:04:46 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

810495

registered interest
date	21/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that it has adequate medical importation and exportation customs expertise after the UK leaves the EU.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	120841
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>Maintaining continuity of medicine supply is a key part of ensuring everyone has continued access to the medicines they need on day one of the United Kingdom’s exit from the European Union and thereafter. The UK is fully committed to continuing the close working relationship with our European partners in the interests of public health and safety; and will seek to ensure that cross-border trade with the EU is as frictionless as possible for the benefit of patients in both the EU and the UK. This will be part of the broader negotiations of the UK’s future relations with the EU and the Department will continue to work closely with Her Majesty’s Revenue and Customs during and after the negotiation period.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2018 15:13:40 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

810496

registered interest
date	21/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that patient access to medicines currently available in the UK is maintained after the UK leaves the EU.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	120842
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120845 120846 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

810499

registered interest
date	21/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of effect of the UK leaving the EU on patients involved in EU clinical trails.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	120845
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120842 120846 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

810500

registered interest
date	21/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials: Rare Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department taking to ensure access to European clinical trails for the treatment of rare diseases by UK patients after the UK has left the EU.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	120846
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120842 120845 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron